Nouvelle déclaration d'incident
No de la demande: 2018-1619
Numéro de référence du titulaire d'homologation: USA-BAYERBAH-2018-US0009137 (Report 475142)
Nom du titulaire (nom légal complet, aucune abbréviation): Bayer inc
Adresse: 2920 Matheson BLVD
Ville: Mississauga
État: ON
Pays: Canada
Code postal /Zip: L5W5R6
Incident chez un animal domestique
Pays: UNITED STATES
État: UNKNOWN
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. 11556-155
Nom du produit: Seresto Small Dog
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. Inconnu
Nom du produit: K9 Advantix II (unspecified)
Autre (préciser)
COLLAR, SPOT ONOui
Autres unités: Collar
Site: Animal / Usage sur un animal domestique
Inconnu
Propriétaire de l'animal
Dog / Chien
Crossbred (Dog)
1
Femme
7
6.804
kg
Cutanée
Unknown / Inconnu
>3 days <=1 wk / >3 jours <=1 sem
Système
Persisted until death
Oui
Non
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On 15-Mar-2018 the dog exhibited multiple seizures. The dog was seen by a veterinarian and treated with diazepam intravenously and an unknown antibiotic. The seizures continued. On 18-Mar-2018 the dog died. No necropsy was performed. No more information is expected. Case is closed.
Mort
O - Unclassifiable/unassessable The product is not anticipated to cause serious neurological disorders such as seizures after appropriate topical product administration as the controlled release mechanism assures release of only low doses of active ingredient at a time. But seizures were reported in connection with product use in dogs and were requested by authorities to be content of the EU SPC. However, it is known that overdose of 5 collars around the neck of adult dogs for an 8 months period and in 7 week old puppies for a 6 months period did not cause serious signs. This is supported by the extremely low systemic exposure with imidacloprid and flumethrin, particularly during the first week after application. Even with oral product exposure, seizures are not seen. Merely gastrointestinal signs may occur. As pet showed seizures prior to product use, seizures are likely related to this underlying condition. It is known that despite adequate treatment, seizures may occur and medication must be adapted every now and then to control the disease. Any action or treatment may trigger seizures in an animal with a respective disposition. Various etiologies exist for seizure events or paroxysmal signs, e.g. heart disorder, development disorder, metabolic disorder, infection, intoxication, idiopathic epilepsy, trauma, neoplasms. Other causes are more likely. Further, death is not expected following appropriate topical product application as inconsistent with product's pharmacological profile. Time to onset is rather long. Considering limited information regarding necropsy report and status of health, overall a product relation is unassessable. N - Unlikely It is known that, at recommended dosage, none of active ingredients in the product have the potential to provoke seizures in dogs neither alone nor in combination. Only mild neurological signs, e.g. tremors or ataxia, may occur even after oral uptake. As dog showed seizures prior to product use, seizures are likely related to this underlying condition. Death is not expected in dog after product application, as inconsistent with pharmaco-toxicological product profile. No signs of allergy/anaphylactic reaction reported. Other etiologies more probable. Considering long time to onset, a product connection is unlikely.